Stay updated with breaking news from Therapeutics Development Network. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Treatment with the once-daily vanza triple CFTR modulator regimen met all primary and key secondary endpoints in two randomized controlled trials in people with CF ages 12 years and older –– Results were more pronounced in the single-arm study in children ages 6 to 11 years, demonstrating the potential that treati...
PDUFA date of May 19, 2023Presented clinical data at ARVO on topical application of B-VEC to the eye to treat ocular complications in a patient with recessive dystrophic epidermolysis bullosa under Compassionate
PDUFA date of May 19, 2023Presented clinical data at ARVO on topical application of B-VEC to the eye to treat ocular complications in a patient with...
/PRNewswire/ -- Bakar Labs, the incubator at UC Berkeley's Bakar BioEnginuity Hub (BBH), announced today a unique collaboration with the Cystic Fibrosis...
/PRNewswire/ -- Bakar Labs, the incubator at UC Berkeley's Bakar BioEnginuity Hub (BBH), announced today a unique collaboration with the Cystic Fibrosis...